2025-06-09-花旗集团-阿尔图拉斯治疗公司（ARCT）_阿尔图拉治疗公司（ARCT.O）2025年第一季度模型更新_13页_596kb

Arcturus Therapeutics (ARCT.O) is a clinical-stage biotech company focused on mRNA therapeutics for rare diseases and infectious conditions, as highlighted in this Citi Research report. The key recommendations are Buy/High Risk for emerging pipeline catalysts, with a price target of $47 from a previous $12.54, reflecting a significant upside in valuation based on cost-saving measures. The company is awaiting critical Phase 2 data updates for ARCT-810 (Ornithine Transcarbamylase Deficiency) in 2Q2025 and ARCT-032 (Cystic Fibrosis) in mid-2025, with an expected catalyst watch expiring by 10 August 2025.

Financial projections show continued losses through 2025-2027, with negative EPS, high debt-to-equity ratios, and declining revenue. However, the analyst assigns a high conviction to the pipeline outcomes, estimating potential global peak sales of $300M for ARCT-810 and $382M for ARCT-032 by 2035 under risk-adjusted scenarios. Risks include potential underperformance of COVID-19 vaccine demand in Japan, which may undercut the Buy thesis. Overall, the stock offers high potential returns but at elevated risk due to biotech volatility.